Comparison · NCT00089674-e3abdd4e
Denosumab 60 mg Q6M vs Placebo: Number of Participants With Any Fracture Through Month 24
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Denosumab 60 mg Q6M vs Placebo: Number of Participants With Any Fracture Through Month 24. Trial comparisons, record NCT00089674-e3abdd4e. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00089674-e3abdd4e
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0436 | 0.031 | 0.0609 | wilson | |
| Risk in group 2 | 0.0613 | 0.0461 | 0.0811 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0177 | -0.0411 | 0.0053 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.711 | 0.457 | 1.11 | log | |
| Odds ratio, group 1 over group 2 | 0.698 | 0.438 | 1.11 | log | |
| Number needed to treat, for one fewer participant with the outcome on Denosumab 60 mg Q6M than on Placebo | 56.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Denosumab 60 mg Q6M | Denosumab 60 mg administered subcutaneous (SC) every 6 months for 3 years | 32 | 734 | OG001 |
| Group 2 | Placebo | Placebo administered subcutaneous every 6 months for 3 years | 45 | 734 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Any Fracture Through Month 24
- Description
- Any fracture includes osteroporotic fractures at any site excluding skull, facial, mandible, metacarpals, finger phalanges, and toe phalanges.
- Time frame
- 24 months
- Population
- Full analysis set
Source ClinicalTrials.gov
Trial
- Title
- AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer
- NCT number
- NCT00089674
- Phases
- PHASE3
- Conditions
- Prostate Cancer
- Interventions
- AMG 162, Placebo
- Lead sponsor
- Amgen
- Results first posted
- 2014-06-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00089674?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00089674-e3abdd4e